Paul Lizzul Sells 3,650 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul Lizzul sold 3,650 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $44.71, for a total transaction of $163,191.50. Following the completion of the transaction, the insider directly owned 42,088 shares in the company, valued at approximately $1,881,754.48. The trade was a 7.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

AnaptysBio Stock Performance

ANAB traded up $0.87 during midday trading on Friday, reaching $44.67. 591,811 shares of the company were exchanged, compared to its average volume of 739,267. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -15.84 and a beta of 0.32. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $52.47. The company’s fifty day moving average price is $42.62 and its 200 day moving average price is $31.46.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The company had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. As a group, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its board has initiated a share buyback program on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Institutional Trading of AnaptysBio

Institutional investors and hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC boosted its holdings in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the period. Bessemer Group Inc. raised its position in shares of AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after buying an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the period. Osaic Holdings Inc. grew its position in AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares in the last quarter. Finally, Covestor Ltd increased its stake in AnaptysBio by 131,540.0% in the 3rd quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 6,577 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ANAB. Barclays cut their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 17th. Wedbush reissued an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research report on Monday, November 24th. Truist Financial upped their price objective on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, November 10th. Stifel Nicolaus lowered their target price on AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Finally, Wells Fargo & Company increased their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $60.40.

AnaptysBio News Summary

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.